X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Hitachi Medical Systems Europe Introduces “LISENDO 880”, th New Premium 2D/4D CARDIOVASCULAR Ultrasound System

Yuvraj_pawp by Yuvraj_pawp
6th December 2017
in Asia, News

Premium cardiac and vascular imaging rises to a new standard as Hitachi Medical Systems Europe introduces its new premium 2D/4D cardiovascular ultrasound system, the LISENDO 880, featuring HDAnalyticsTM, a unique and accurate cardiovascular analysis package for confident cardiac hemodynamic assessments, at EuroEcho Imaging 2017 in Lisbon, Portugal, December 6, 2017.

Since their inception, today’s ultrasound systems have progressed to become essential medical devices for all levels of cardiovascular care. The LISENDO 880 is Hitachi’s new premium 2D/4D diagnostic ultrasound solution for cardiologists that redefines the vision of cardiac ultrasound by providing exceptional clinical performance coupled with state-of-the-art features and analytics.

Hitachi released the world’s first diagnostic ultrasound system in 1960 and the world’s first Colour Doppler ultrasound system in 1983. Continuing this history of innovation, Hitachi introduced Vector Flow Mapping (VFM) analysis using ultrasound in 2013. Hitachi stands out as a company dedicated to providing unique solutions to echocardiography’s clinical challenges. The LISENDO 880 maintains Hitachi’s tradition of providing exceptionally innovative ultrasound for cardiovascular care.

The LISENDO 880 was developed to address the most important needs for cardiovascular imaging:

Pure Image Technology
The advanced architecture of the LISENDO 880 offers state-of-the-art transducer technology for 2D/4D imaging, a high performance OLED display, premium image optimization parameters such as eFocusing and Pure Symphonic Architecture to capture the subtlest of changes and produce the highest-quality ‘sound’.

Seamless Workflow
The LISENDO 880 was designed to provide maximum scanning comfort, along with state-of-the-art technology to help you complete your exams more easily. LISENDO’s flexible positioning which includes a four-point articulating monitor arm and adjustable panel height, supports comfortable operation while the operation panel allows ergonomic function adjustment as a part of our intuitive user interface. LISENDO 880 delivers seamless workflow users expect in a premium ultrasound system.

Additionally, LISENDO 880 is equipped with a sophisticated automatic anatomy recognition and cardiac function measurement package based on our HDSI (HemoDynamic Structural Intelligence). Smart cardiac measurements, using learning data structured by Hitachi’s big data and Artificial Intelligence (AI) technology significantly improve the examination efficiency and create new value with Hitachi’s unique solutions.

Your Application
The LISENDO 880 is Hitachi’s most advanced ultrasound system offering premium 2D/4D cardiovascular applications and innovative cardiac imaging features, namely the unique HDAnalytics™ (HemoDynamic Analytics) package which includes LVeFlow, iDGD (Dual Gate Doppler) with R-R Navigation, VFM (Vector Flow Mapping) and eTRACKING with Wave Intensity. In addition, LISENDO 880 offers the Eyeball EF and i2DTT quantification tools.

With these features, LISENDO 880 moves cardiac evaluations to a new level and maintains Hitachi’s tradition of providing exceptionally innovative ultrasound for cardiovascular care.

About Hitachi Medical Systems Europe
Hitachi Healthcare in Europe is represented by Hitachi Medical Systems Europe Holding AG, Zug, Switzerland. The company is a first choice supplier of open and powerful high-field MRI systems, multi-slice CT systems as well as medical ultrasound, endoscopic and optical topography systems (NIRS). Ultrasound expertise encompasses clinical applications such as cardiology, radiology, internal medicine, obstetrics/gynecology, gastroenterology, urology and surgery. Hitachi Medical Systems Europe offers a complete range of solutions to address a wide range of medical challenges. For more information about Hitachi Medical Systems Europe Holding AG,

For more information, please visit http://www.hitachi-medical-systems.eu

About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges. The company’s consolidated revenues for fiscal 2016 (ended March 31, 2017) totaled 9,162.2 billion yen ($81.8 billion). The Hitachi Group is a global leader in the Social Innovation Business, and it has approximately 304,000 employees worldwide. Through collaborative creation, Hitachi is providing solutions to customers in a broad range of sectors, including Power / Energy, Industry / Distribution / Water, Urban Development, and Finance / Government & Public / Healthcare. For more information on Hitachi, please visit the company’s website at http://www.hitachi.com

Contact:
Romea Wallnoefer
Hitachi Medical Systems Europe Holding AG
r.wallnoefer@hitachi-medical-systems.com
+41-41-748-63-33

Previous Post

Canon BioMedical products now available in Austria, Germany, and Switzerland

Next Post

Johnson & Johnson Announces Development Of Zika Vaccine

Related Posts

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
Next Post

Johnson & Johnson Announces Development Of Zika Vaccine

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In